4.8 Article

Structural basis of second-generation HIV integrase inhibitor action and viral resistance

Journal

SCIENCE
Volume 367, Issue 6479, Pages 806-+

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.aay4919

Keywords

-

Funding

  1. U.S.National Institutes of Health [P50 AI150481, R01 AI070042]
  2. Francis Crick Institute
  3. Cancer Research UK [FC001061]
  4. UK Medical Research Council [FC001061]
  5. Wellcome Trust [FC001061]
  6. EPSRC [EP/R013012/1, EP/R029407/1]
  7. ERC [757850 BioNet]
  8. EPSRC [EP/R013012/1, EP/L000253/1, EP/M022609/1] Funding Source: UKRI

Ask authors/readers for more resources

Although second-generation HIV integrase strand-transfer inhibitors (INSTIs) are prescribed throughout the world, the mechanistic basis for the superiority of these drugs is poorly understood. We used single-particle cryo-electron microscopy to visualize the mode of action of the advanced INSTIs dolutegravir and bictegravir at near-atomic resolution. Glutamine-148 -> histidine (Q148H) and glycine-140 -> serine (G140S) amino acid substitutions in integrase that result in clinical INSTI failure perturb optimal magnesium ion coordination in the enzyme active site. The expanded chemical scaffolds of second-generation compounds mediate interactions with the protein backbone that are critical for antagonizing viruses containing the Q148H and G140S mutations. Our results reveal that binding to magnesium ions underpins a fundamental weakness of the INSTI pharmacophore that is exploited by the virus to engender resistance and provide a structural framework for the development of this class of anti-HIV/AIDS therapeutics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available